ZS Acquires Digital Health Specialist Medullan to Help Accelerate Innovation for Life Sciences
Acquisition is largest in 37-year history of ZS.
Global professional services firm ZS has announced it is acquiring Medullan, a digital medicine strategies and solutions company.
Medullan has developed specialized resources and tools in the digital medicine space, such as the pioneering virtual care and decentralized trial platform, VARA™.
The acquisition is the largest in the history of ZS, a 37-year-old company that now employs over 8,000 professionals across more than 25 offices worldwide. When the transaction is finalized, Medullan’s 80-plus employees will join ZS’s DCH practice.
“Digital health solutions will transform how we experience healthcare, improve lives and reduce costs in the process. While significant progress has been made, there remain many challenges to overcome toward realizing this vision,” said Pete Masloski, principal at ZS and leader of the DCH practice, which Medullan employees will join.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
